🚀 VC round data is live in beta, check it out!
Oncodesign Precision Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oncodesign Precision Medicine and similar public comparables like Akari Therapeutics, Exact Therapeutics, Alligator Bioscience, Coegin Pharm and more.
Oncodesign Precision Medicine Overview
About Oncodesign Precision Medicine
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
Founded
1995
HQ
Employees
19
Website
Sectors
Financials (FY)
EV
$15M
Oncodesign Precision Medicine Financials
Oncodesign Precision Medicine reported last fiscal year revenue of $240K and negative EBITDA of ($8M).
In the same fiscal year, Oncodesign Precision Medicine generated ($7M) in gross profit, ($8M) in EBITDA losses, and had net loss of ($8M).
Revenue (LTM)
Oncodesign Precision Medicine P&L
In the most recent fiscal year, Oncodesign Precision Medicine reported revenue of $240K and EBITDA of ($8M).
Oncodesign Precision Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $240K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($7M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (3040%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3508%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (3566%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (3292%) | XXX | XXX | XXX |
| Net Debt | — | — | $8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oncodesign Precision Medicine Stock Performance
Oncodesign Precision Medicine has current market cap of $11M, and enterprise value of $15M.
Market Cap Evolution
Oncodesign Precision Medicine's stock price is $0.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15M | $11M | (0.2%) | XXX | XXX | XXX | $-0.43 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOncodesign Precision Medicine Valuation Multiples
Oncodesign Precision Medicine trades at 63.8x EV/Revenue multiple, and (1.8x) EV/EBITDA.
EV / Revenue (LTM)
Oncodesign Precision Medicine Financial Valuation Multiples
As of March 7, 2026, Oncodesign Precision Medicine has market cap of $11M and EV of $15M.
Equity research analysts estimate Oncodesign Precision Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncodesign Precision Medicine has a P/E ratio of (1.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | $15M | XXX | $15M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 63.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (2.1x) | XXX | XXX | XXX |
| P/E | — | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oncodesign Precision Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oncodesign Precision Medicine Margins & Growth Rates
Oncodesign Precision Medicine's revenue in the last fiscal year declined by (81%).
Oncodesign Precision Medicine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (81%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3508%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (23%) | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 731% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oncodesign Precision Medicine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Akari Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Exact Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alligator Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Coegin Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Biosergen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncodesign Precision Medicine M&A Activity
Oncodesign Precision Medicine acquired XXX companies to date.
Last acquisition by Oncodesign Precision Medicine was on XXXXXXXX, XXXXX. Oncodesign Precision Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oncodesign Precision Medicine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOncodesign Precision Medicine Investment Activity
Oncodesign Precision Medicine invested in XXX companies to date.
Oncodesign Precision Medicine made its latest investment on XXXXXXXX, XXXXX. Oncodesign Precision Medicine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oncodesign Precision Medicine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oncodesign Precision Medicine
| When was Oncodesign Precision Medicine founded? | Oncodesign Precision Medicine was founded in 1995. |
| Where is Oncodesign Precision Medicine headquartered? | Oncodesign Precision Medicine is headquartered in France. |
| How many employees does Oncodesign Precision Medicine have? | As of today, Oncodesign Precision Medicine has over 19 employees. |
| Is Oncodesign Precision Medicine publicly listed? | Yes, Oncodesign Precision Medicine is a public company listed on Euronext Paris. |
| What is the stock symbol of Oncodesign Precision Medicine? | Oncodesign Precision Medicine trades under ALOPM ticker. |
| When did Oncodesign Precision Medicine go public? | Oncodesign Precision Medicine went public in 2022. |
| Who are competitors of Oncodesign Precision Medicine? | Oncodesign Precision Medicine main competitors are Akari Therapeutics, Exact Therapeutics, Alligator Bioscience, Coegin Pharm. |
| What is the current market cap of Oncodesign Precision Medicine? | Oncodesign Precision Medicine's current market cap is $11M. |
| What is the current revenue of Oncodesign Precision Medicine? | Oncodesign Precision Medicine's last fiscal year revenue is $240K. |
| What is the current EV/Revenue multiple of Oncodesign Precision Medicine? | Current revenue multiple of Oncodesign Precision Medicine is 63.8x. |
| Is Oncodesign Precision Medicine profitable? | No, Oncodesign Precision Medicine is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.